c diff quik chek complete immunochromatographic assay (Abbott Laboratories)
86
Structured Review
Abbott Laboratories
c diff quik chek complete immunochromatographic assay
C Diff Quik Chek Complete Immunochromatographic Assay, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+diff+quik+chek+complete/c+chek+complete+diff+quik/pm41745777-248-15-22
Average 86 stars, based on 1 article reviews
C Diff Quik Chek Complete Immunochromatographic Assay, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/c+diff+quik+chek+complete/c+chek+complete+diff+quik/pm41745777-248-15-22
Average 86 stars, based on 1 article reviews
c diff quik chek complete immunochromatographic assay - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Stable Clostridioides difficile infection rates after the discontinuation of ultraviolet light for terminal disinfection at a tertiary care center, Iowa 2019-2020. Article Snippet: Oluchi J. Abosi MB ChB, MPH, CIC *, Takaaki Kobayashi MD , Stephanie Holley MBA, BSN, CIC , Mary Elizabeth Kukla BSN, RN, CIC , Angelique Dains BSN, RN, CIC , Mohammed Alsuhaibani MBBS , Alexandre R. Marra MD , Kyle E. Jenn BSN, RN , Holly MeachamMSN, RN , Lorinda L. Sheeler PhD , William Etienne MD, MPH, CIC , Alexandra Trannel MS , Jon Garringer CMIP , William Millard CHESP, CMIP , Daniel J. Diekema MD, MS , Michael B. Edmond MD, MPH, MPA, MBA , Melanie Wellington MD, PhD , Jorge L. Salinas MD a Article Title: Evaluation of 4 molecular assays as part of a 2-step algorithm for the detection of Clostridium difficile in stool specimens. Article Snippet: Abbreviations: CCFA, cycloserine-cefoxitin-fructose agar immunoassay; FDA, US Food and Drug Administration; G HDA, helicase-dependent amplification; IDSA, Infectiou LAMP, loop-mediated isothermal DNA amplification; NAAT NPV, negative predictive value; PaLoc, pathogenicity locus; PPV, positive predictive value; SHEA, Society for Healthcare ☆ Mayo Clinic does not endorse specific products or ser ☆☆ Conflict of interest: None.. ⁎ Corresponding author.. Tel. Amplification:Article Title: Stable Clostridioides difficile infection rates after the discontinuation of ultraviolet light for terminal disinfection at a tertiary care center, Iowa 2019-2020. Article Snippet: Oluchi J. Abosi MB ChB, MPH, CIC *, Takaaki Kobayashi MD , Stephanie Holley MBA, BSN, CIC , Mary Elizabeth Kukla BSN, RN, CIC , Angelique Dains BSN, RN, CIC , Mohammed Alsuhaibani MBBS , Alexandre R. Marra MD , Kyle E. Jenn BSN, RN , Holly MeachamMSN, RN , Lorinda L. Sheeler PhD , William Etienne MD, MPH, CIC , Alexandra Trannel MS , Jon Garringer CMIP , William Millard CHESP, CMIP , Daniel J. Diekema MD, MS , Michael B. Edmond MD, MPH, MPA, MBA , Melanie Wellington MD, PhD , Jorge L. Salinas MD a Diff-Quik:Article Title: Stable Clostridioides difficile infection rates after the discontinuation of ultraviolet light for terminal disinfection at a tertiary care center, Iowa 2019-2020. Article Snippet: Oluchi J. Abosi MB ChB, MPH, CIC *, Takaaki Kobayashi MD , Stephanie Holley MBA, BSN, CIC , Mary Elizabeth Kukla BSN, RN, CIC , Angelique Dains BSN, RN, CIC , Mohammed Alsuhaibani MBBS , Alexandre R. Marra MD , Kyle E. Jenn BSN, RN , Holly MeachamMSN, RN , Lorinda L. Sheeler PhD , William Etienne MD, MPH, CIC , Alexandra Trannel MS , Jon Garringer CMIP , William Millard CHESP, CMIP , Daniel J. Diekema MD, MS , Michael B. Edmond MD, MPH, MPA, MBA , Melanie Wellington MD, PhD , Jorge L. Salinas MD a Article Title: Evaluation of 4 molecular assays as part of a 2-step algorithm for the detection of Clostridium difficile in stool specimens. Article Snippet: Abbreviations: CCFA, cycloserine-cefoxitin-fructose agar immunoassay; FDA, US Food and Drug Administration; G HDA, helicase-dependent amplification; IDSA, Infectiou LAMP, loop-mediated isothermal DNA amplification; NAAT NPV, negative predictive value; PaLoc, pathogenicity locus; PPV, positive predictive value; SHEA, Society for Healthcare ☆ Mayo Clinic does not endorse specific products or ser ☆☆ Conflict of interest: None.. ⁎ Corresponding author.. Tel. Article Title: Clostridioides difficile colonization and infection in a cohort of Australian adults with cystic fibrosis. Article Snippet: Clostridioides difficile colonization and infection in a cohort of Australian adults with cystic fibrosis A.S. Tai a,b,c,y, P. Putsathit d,y, L. Eng , K. Imwattana , D.A.. Collins , S. Mulrennan , T.V.. Riley b,d,e, f, * Western Australia Adult Cystic Fibrosis Centre, Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia b School of Biomedical Sciences, Faculty of Health and Medical Sciences, The University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia c Institute for Respiratory Health, The Harry Perkins Institute ofMedical Research, Queen Elizabeth II Medical Centre, Nedlands,WA, Australia d School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia Medical, Molecular and Forensic Sciences, Murdoch University, Murdoch, WA, Australia Department of Microbiology, PathWest Laboratory Medicine, Queen Elizabeth II Medical Centre, Nedlands, WA, Australia Article Title: Characterization of Circulating Clostridium difficile Strains, Host Response and Intestinal Microbiome in Hospitalized Children With Diarrhea Article Snippet: .. All stool samples underwent alcohol-shock treatment, followed by culture for C. difficile on Brazier’s cefoxitin-cycloserine egg yolk agar as previously described.18 Samples underwent lateral flow testing for the presence of C. difficile glutamate dehydrogenase and the presence of toxins A and/or B with Article Title: Molecular characterization of Clostridioides difficile isolated from older adults during prospective population-based active surveillance at nine hospitals in Tokyo, Japan, 2018-2020. Article Snippet: Background: To characterize Clostridioides difficile isolates identified during a prospective multi-hospital population-based study of C. difficile infection (CDI).. Methods: Between December 2018 and March 2020, inpatients ≥50 years of age with new-onset diarrhea in nine Tokyo hospitals were investigated for CDI.. Stool specimens were screened by C. DIFF QUIK CHEK COMPLETE® and glutamate dehydrogenase (GDH) positive stools tested by Xpert® C. difficile/Epi PCR assay. Membrane:Article Title: Evaluation of 4 molecular assays as part of a 2-step algorithm for the detection of Clostridium difficile in stool specimens. Article Snippet: Abbreviations: CCFA, cycloserine-cefoxitin-fructose agar immunoassay; FDA, US Food and Drug Administration; G HDA, helicase-dependent amplification; IDSA, Infectiou LAMP, loop-mediated isothermal DNA amplification; NAAT NPV, negative predictive value; PaLoc, pathogenicity locus; PPV, positive predictive value; SHEA, Society for Healthcare ☆ Mayo Clinic does not endorse specific products or ser ☆☆ Conflict of interest: None.. ⁎ Corresponding author.. Tel. Polymerase Chain Reaction:Article Title: Molecular characterization of Clostridioides difficile isolated from older adults during prospective population-based active surveillance at nine hospitals in Tokyo, Japan, 2018-2020. Article Snippet: Background: To characterize Clostridioides difficile isolates identified during a prospective multi-hospital population-based study of C. difficile infection (CDI).. Methods: Between December 2018 and March 2020, inpatients ≥50 years of age with new-onset diarrhea in nine Tokyo hospitals were investigated for CDI.. Stool specimens were screened by C. DIFF QUIK CHEK COMPLETE® and glutamate dehydrogenase (GDH) positive stools tested by Xpert® C. difficile/Epi PCR assay. |